Short Interest in Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Rises By 20.4%

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 136,200 shares, a growth of 20.4% from the February 13th total of 113,100 shares. Based on an average daily volume of 39,400 shares, the days-to-cover ratio is currently 3.5 days.

Cipher Pharmaceuticals Stock Performance

Shares of CPHRF stock traded up $0.47 during mid-day trading on Wednesday, hitting $8.37. 3,428 shares of the stock traded hands, compared to its average volume of 17,797. Cipher Pharmaceuticals has a 52-week low of $5.62 and a 52-week high of $14.60. The stock’s fifty day moving average is $9.03 and its two-hundred day moving average is $10.36.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.